Released May 8, 2025, after the close
10-Q filed May 8, 2025, 38 days after period end · 0001410578-25-001112
Q1 2025 · 10-Q
Revenue$2.34M$2.34M +92.0% vs Q1 2024−41.9% vs Q4 2024
Net Income-$10.72M-$10.72M N/M vs Q1 2024N/M vs Q4 2024
EPS Diluted$0.36$0.36 +33.3% vs Q1 2024no prior Q4 2024 on file
Gross Profit$1,853,000+114.0%
Operating Income-$11,166,000N/M
Operating Cash Flow-$8,283,000N/M
Margins · derived
Gross margin79.2%+8.1 pt vs Q1 2024
Operating margin-477.0%+169.2 pt vs Q1 2024
Net margin-458.1%+82.1 pt vs Q1 2024
What the release said
The release
Same quarter
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $2.34M | $1.22M |
| Net Income | -$10.72M | -$6.59M |
| EPS Diluted | $0.36 | $0.27 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Profound Medical Corp. · CIK 1628808 · Engraved from SEC EDGAR